shire map
Select a
Location

Shire Global

Leadership

Steven Gillis, PhD

Steven GillisNon-Executive Director

Appointed: October 1, 2012

Committee membership: Audit, Compliance & Risk Committee, Remuneration Committee and Science & Technology Committee

Skills & experience: Steven brings to the Board his extensive technical and scientific knowledge and commercial experience. He is currently a Managing Director at ARCH Venture Partners; a provider of venture capital for technology firms. Prior to this Steven was a founder and Director of Corixa Corporation, acquired by GlaxoSmithKline in 2005, and before that a founder and Director of Immunex Corporation. An immunologist by training Steven has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Steven received his BA from Williams College and his PhD from Dartmouth College.

Key appointments: ARCH Venture Partners (Managing Director), Pulmatrix, Inc. (Non-Executive Director), PhaseRx Inc. (Chairman and Non-Executive Director) and VBI Vaccines Inc. (Chairman and Non-Executive Director).

Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our cookie notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE